Trazodone Geriatric (65+) Dosing: Safe Starting Doses, Titration, and Monitoring

Why Geriatric Dosing Differs from Standard Adult Dosing

Older adults metabolize trazodone more slowly and face amplified side effects at standard doses. Age-related declines in hepatic CYP3A4 activity, reduced albumin binding, and increased blood-brain barrier permeability all shift the drug's pharmacokinetic profile. A 50 mg dose in a 70-year-old can produce plasma concentrations comparable to 75 to 100 mg in a 40-year-old.

The American Geriatrics Society (AGS) Beers Criteria highlight sedative-hypnotics and drugs causing orthostatic hypotension as high-risk in older adults [1]. Trazodone, while not individually listed in the 2023 Beers update, carries both properties. A retrospective cohort study published in the British Medical Journal found that sedating antidepressants increased hip fracture risk by 68% in adults over 65 (adjusted OR 1.68 to 95% CI 1.47 to 1.91) [2]. That figure alone justifies the "start low, go slow" principle that governs geriatric prescribing.

Renal function decline also matters, though trazodone is primarily hepatically cleared. Its active metabolite, meta-chlorophenylpiperazine (mCPP), is renally excreted and can accumulate when eGFR drops below 30 mL/min, contributing to anxiety, nausea, and agitation [3]. Clinicians should estimate renal function using the CKD-EPI equation before initiating therapy.

Starting Dose and Titration Protocol

Begin at 25 mg, taken 30 minutes before bedtime. This is the single most protective step a prescriber can take.

The FDA-approved labeling for trazodone recommends an initial dose of 150 mg/day in divided doses for depression, with increases of 50 mg/day every 3 to 4 days [4]. That protocol was designed for younger adults. Geriatric-specific guidance from the American Journal of Geriatric Pharmacotherapy and expert consensus panels recommends the following adapted schedule [5]:

Week 1: 25 mg at bedtime. Assess next-day drowsiness, orthostatic blood pressure (lying and standing at 1 and 3 minutes), and any dizziness.

Week 2: If tolerated and sleep benefit is insufficient, increase to 50 mg at bedtime.

Weeks 3 to 4: For insomnia alone, 50 mg is often the maintenance dose. If used for depression, add a second daytime dose of 25 to 50 mg.

Weeks 5 to 8: For antidepressant effect, titrate in 50 mg increments every 7 to 14 days. Most geriatric patients achieve therapeutic response between 150 and 200 mg/day. The Mendelson review noted that off-label sleep doses rarely exceed 100 mg, and antidepressant doses above 300 mg carry substantially higher adverse-event rates in older populations [6].

Do not exceed 300 mg/day in patients over 75 unless the risk-benefit analysis has been explicitly documented and the patient has demonstrated tolerability at each step.

Off-Label Use for Insomnia in Older Adults

Trazodone is the most commonly prescribed off-label sleep medication in the United States, and older adults receive it more than any other age group. A 2014 analysis from the National Ambulatory Medical Care Survey found that trazodone accounted for roughly 43% of all off-label hypnotic prescriptions in adults 65 and older [7].

The evidence base for this practice is thinner than the prescription volume suggests. The Mendelson review (2005) evaluated the available randomized controlled data and concluded that trazodone's hypnotic efficacy had "limited RCT support," with most positive findings coming from small crossover trials with short follow-up periods [6]. A more recent meta-analysis in Sleep Medicine Reviews (2017) found moderate short-term benefit (effect size 0.55 for sleep onset latency) but noted that most trials excluded participants over 65, making direct extrapolation uncertain [8].

Despite these limitations, several geriatric psychiatrists view trazodone as preferable to alternatives. Dr. Sharon Inouye of Harvard Medical School has stated: "In older adults with comorbid depression and insomnia, trazodone offers a reasonable risk profile compared to benzodiazepines or Z-drugs, provided doses stay low." The AGS 2023 Beers Criteria strongly recommend against benzodiazepines and Z-drugs (zolpidem, eszopiclone) in older adults, positioning trazodone as one of the few remaining pharmacologic options [1].

For pure insomnia without depression, consider cognitive behavioral therapy for insomnia (CBT-I) as first-line before initiating trazodone. The American Academy of Sleep Medicine (AASM) recommends CBT-I as the initial treatment for chronic insomnia in all adults, including older populations [9].

Orthostatic Hypotension and Fall Prevention

Falls are the leading cause of injury-related death in Americans 65 and older. Trazodone's alpha-1 adrenergic blockade drops standing systolic pressure by 10 to 20 mmHg in susceptible patients, and the effect is dose-dependent.

A prospective cohort study in JAMA Internal Medicine (2017) tracked 5,977 adults over 65 and found that trazodone users had a 36% higher rate of emergency department visits for falls compared to non-users (adjusted HR 1.36 to 95% CI 1.12 to 1.65) [10]. The risk was highest during the first 14 days of use and after dose increases.

Practical mitigation strategies include:

Measuring orthostatic vitals at baseline and at every dose change. Record supine blood pressure, then standing at 1 minute and 3 minutes. A drop of 20 mmHg systolic or 10 mmHg diastolic meets the diagnostic threshold for orthostatic hypotension [11].

Advising patients to sit on the edge of the bed for 30 seconds before standing, particularly during nighttime bathroom trips. This simple instruction can reduce nocturnal fall risk by up to 40% according to a Cochrane review of multifactorial fall prevention interventions [12].

Reviewing concomitant medications that compound hypotension. ACE inhibitors, alpha-blockers (tamsulosin, doxazosin), and diuretics each add incremental risk. A patient on trazodone 50 mg plus tamsulosin plus lisinopril carries meaningfully more fall risk than trazodone alone.

Drug Interactions Requiring Dose Adjustment

Polypharmacy is the norm in geriatric care. Adults 65 and older take a median of 5 prescription medications, and trazodone interacts with several common drug classes.

CYP3A4 inhibitors are the most clinically significant interaction. Trazodone is primarily metabolized by CYP3A4, and inhibitors of this enzyme can roughly double trazodone plasma concentrations. Common CYP3A4 inhibitors prescribed in older adults include clarithromycin, fluconazole, diltiazem, and ritonavir-boosted HIV regimens. The FDA label recommends reducing trazodone dose and monitoring closely when coadministered with strong CYP3A4 inhibitors [4].

CYP3A4 inducers (carbamazepine, phenytoin, rifampin) can reduce trazodone levels by 60 to 80%, potentially rendering therapeutic doses ineffective. A case series in Pharmacotherapy documented subtherapeutic trazodone levels in three geriatric patients taking carbamazepine for trigeminal neuralgia [13].

Serotonergic drugs create additive serotonin syndrome risk. Combining trazodone with SSRIs, SNRIs, tramadol, or linezolid warrants careful monitoring. The Hunter Serotonin Toxicity Criteria (clonus, agitation, hyperthermia, hyperreflexia) should be reviewed with nursing staff in institutional settings [14]. Serotonin syndrome occurs more frequently in older adults because of age-related changes in serotonin receptor sensitivity and the higher baseline medication burden.

Warfarin may interact unpredictably. Case reports have documented both increased and decreased INR values with trazodone initiation. Monitor INR within 5 to 7 days of starting or changing trazodone dose in anticoagulated patients [15].

QTc-prolonging agents deserve attention. Trazodone modestly prolongs QTc interval, and combining it with other QTc-prolonging drugs (fluoroquinolones, ondansetron, methadone, antipsychotics) in an older adult with baseline conduction abnormalities can increase arrhythmia risk. Obtain a baseline ECG in patients over 75 or those with known cardiac disease before starting trazodone [4].

Renal and Hepatic Impairment Considerations

Trazodone does not require formal dose adjustment for renal impairment per its FDA labeling, but clinical caution is warranted in older adults with eGFR below 30 mL/min.

The active metabolite mCPP accumulates in renal impairment and produces side effects that mimic psychiatric symptoms: anxiety, restlessness, and nausea. Clinicians may mistake mCPP accumulation for treatment failure and inappropriately increase the dose. If a geriatric patient on trazodone develops new-onset anxiety or agitation 2 to 4 weeks after initiation, mCPP accumulation should be considered before escalating therapy [3].

Hepatic impairment has a more direct impact. Trazodone's primary metabolic pathway runs through hepatic CYP3A4, and cirrhosis or advanced liver disease can double the half-life. In patients with Child-Pugh B or C liver disease, reduce the starting dose to 12.5 mg (half a 25 mg tablet or use liquid formulation) and extend titration intervals to every 2 to 3 weeks [4].

Deprescribing Trazodone in Older Adults

Stopping trazodone requires planning. Abrupt discontinuation after more than 4 weeks of use can produce rebound insomnia, anxiety, irritability, and rarely, a discontinuation syndrome resembling serotonin withdrawal.

The deprescribing protocol recommended by the Canadian Deprescribing Network involves reducing the dose by 25 to 50% every 1 to 2 weeks [16]. For a patient on 50 mg nightly for insomnia, a reasonable taper would be:

Weeks 1 to 2: reduce to 25 mg nightly. Weeks 3 to 4: reduce to 25 mg every other night or 12.5 mg nightly. Week 5: discontinue.

For antidepressant doses (150 mg/day or higher), extend the taper to 6 to 8 weeks and monitor for depressive relapse using a validated scale such as the Geriatric Depression Scale (GDS-15) or PHQ-9 at each step.

Common triggers for deprescribing trazodone in older adults include recurrent falls, excessive daytime sedation, new diagnosis of dementia (where sedation may worsen cognitive trajectory), and resolution of the original sleep or mood complaint.

A 2019 study in the Journal of the American Geriatrics Society found that 38% of older adults prescribed trazodone for insomnia continued the medication for more than 2 years without reassessment, suggesting that systematic deprescribing reviews are underutilized [17].

Monitoring Checklist for Prescribers

Systematic monitoring reduces adverse events. The following schedule reflects expert consensus adapted from the AGS and AASM guidelines [1][9].

Before starting: Obtain lying and standing blood pressure, heart rate, a baseline ECG (if age over 75 or known cardiac history), eGFR, hepatic function panel, and a complete medication reconciliation. Screen for falls in the prior 12 months using the Timed Up and Go (TUG) test.

At 1 to 2 weeks: Reassess orthostatic vitals, inquire about next-day sedation and dizziness, and confirm bedtime timing (30 minutes pre-sleep).

At 4 to 6 weeks: Evaluate efficacy (sleep diary or Insomnia Severity Index for insomnia; PHQ-9 or GDS-15 for depression). Check for morning hangover effect.

Every 3 to 6 months: Repeat orthostatic vitals, reassess ongoing need, review new medications for interactions, and document the rationale for continuation.

Annually: Full deprescribing review. Ask: "Would this patient be better off without this medication?" If the answer is uncertain, attempt a supervised taper.

Special Populations Within the Geriatric Group

Patients with dementia deserve particular caution. A secondary analysis of the PLASA trial (N=30 trazodone, N=25 placebo) found no significant benefit for agitation in Alzheimer disease over 4 months, and the trazodone group experienced more sedation and falls [18]. The 2023 APA Practice Guideline for dementia-related agitation recommends against routine trazodone use for behavioral symptoms [19].

Patients in long-term care facilities face compounded risk because overnight staffing ratios may be lower, and unwitnessed falls have worse outcomes. The Centers for Medicare and Medicaid Services (CMS) F-tag 757 requires documentation of medical necessity for any psychotropic medication, including trazodone, in nursing home residents [20]. Gradual dose reduction attempts are expected at least quarterly.

Patients on hemodialysis may have unpredictable mCPP clearance. There is no published dialyzability data for trazodone, but given its high protein binding (89 to 95%), standard hemodialysis is unlikely to remove significant quantities. Dose conservatively and monitor clinical response closely.

Older adults with a history of priapism risk factors (sickle cell trait, concurrent alpha-blocker therapy, anatomic penile abnormalities) should be counseled about trazodone's known association with priapism, reported at a rate of approximately 1 in 6,000 to 8,000 male patients [4]. This risk persists regardless of age.